خواص دارویی و گیاهی
UK Edition. Click here for US version.
Active substance(s): FEXOFENADINE HYDROCHLORIDE
PDF options: View Fullscreen Download PDF
+ Expand Transcript
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.داروی telfast 120mg
Medical Disclaimer
The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.
Subscribe to Drugs.com newsletters for the latest medication news, alerts, new drug approvals and more.
Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include IBM Watson Micromedex (updated 1 July 2019), Cerner Multum™ (updated 1 July 2019), Wolters Kluwer™ (updated 29 June 2019) and others.
Third Party Advertising
We comply with the HONcode standard for trustworthy health information – verify here
Copyright © 2000-2019 Drugs.com. All rights reserved.
مجری طرح پایلوت : انجمن داروسازان اصفهان
تحت نظارت معاونت غذا و دارو
مسئولیت صحت اطلاعات بر عهده داروخانه می باشد
*دریافت دارو فقط بصورت حضوری در محل داروخانه و با نسخه کامل امکان پذیر است*
تلفست چیست؟
تلفست حاوی نوعی آنتی هیستامین به نام فکسوفنادین است. فکسوفنادین نسل دوم داروهای آنتی هیستامین است. این دارو در بالغین و کودکان بالای 12 سال برای رفع علائم آلرژی فصلی ( تب یونجه) شامل عطسه، خارش و آبریزش یا انسداد بینی و خارش و قرمزی و آبریزش چشم ها استفاده می شود. این دارو توسط شرکت سنوفی اونتیس فرانسه تولید می شود و توسط شرکت کوبل دارو وارد کشور می شودداروی telfast 120mg
موارد منع مصرف:
حساسیت به فکسوفنادین یا هر یک از اجزای این دارو
موارد احتیاط:
در موارد زیر قبل از مصرف تلفست با پزشک یا داروساز مشورت نمایید:
اختلال کبدی یا کلیوی
ابتلا به بیماری قلبی یا سابقه آن، زیرا این دارو ممکن است موجب افزایش یا نامنظم شدن ضربان قلب شود.
در سالمندان
در صورت وجود هر یک از موارد ذکر شده یا وجود هر گونه تردید، پیش از مصرف دارو با پزشک مشورت کنید.
مصرف تلفست بیش از حد مجاز:
در صورت مصرف بیش از حد دارو فوراً به پزشک یا بیمارستان مراجعه کنید. علائم عبارتند از سرگیجه، خواب آلودگی، خستگی و خشکی دهان.
فراموش کردن مصرف تلفست:
از 2 برابر کردن دوز دارو برای جبران دوز فراموش شده(مصرف دو دوز به صورت همزمان) خودداری نمایید و دوز بعدی را در زمان معمول آن مصرف کنید.
توقف مصرف تلفست:
در صورت تمایل به قطع دارو پیش از اتمام دوره درمان، به پزشک اطلاع دهید. در صورت توقف دارو زودتر از زمان مورد نظر، ممکن است دچار عود علائم شوید.
عوارض جانبی تلفست
مصرف تلفست مانند هر دارویی ممکن است تعدادی عارضه جانبی در پی داشته باشد، اگرچه این عوارض در تمام افراد بروز نمی کنند.
در صورت ایجاد علائم زیر مصرف دارو را متوقف و فوراً به پزشک مراجعه کنید:
تورم صورت، لب ها، زبان، گلو و تنگی نفس که ممکن است نشانه واکنش حساسیتی خطرناک باشند.
عوارض شایع (بروز در یک مورد به ازای هر 10 نفر):
سردرد
احساس رخوت
تهوع
سرگیجه
عوارض ناشایع (بروز در یک مورد به ازای هر 100 نفر):
خستگی
خواب آلودگی
سایرعوارض جانبی با فراوانی ناشناخته (غیرقابل ارزیابی بر اساس اطلاعات موجود):
بی خوابی
اختلالات خواب
کابوس
عصبانیت
ضربان تند یا نامنظم قلب
اسهال
دانه های پوستی و خارش
کهیر
واکنش های آلرژیک شدید باعلائم تورم صورت، لب ها، زبان، گلو، گرگرفتگی، احساس فشار در قفسه سینه و تنگی نفس
نحوه نگهداری دارو
دارو را دور از دسترس کودکان نگه دارید.
از مصرف دارو پس از تاریخ انقضا که روی بسته بندی درج شده است خودداری نمایید. منظور از تاریخ انقضا آخرین روز از ماه ذکر شده می باشد.
این دارو نیاز به شرایط نگهداری خاصی ندارد.
محتویات تلفست 120
هر قرص تلفست ۱۲۰ محتوی ۱۲۰ میلی گرم فکسوفنادین است. قرص تلفست ۱۲۰ به رنگ صورتی و شبیه کپسول است.
Reference: https://www.cobeldarou.com/fa/content/telfast
Reference: https://www.drugs.com/cdi/fexofenadine-tablets.html
Reference: https://telfast.com.au/
چنانچه در خصوص “قرص تلفست 120 میلی گرم” سوالی دارید، عارضه خاصی مشاهده نموده اید و یا مطلب ویژه ای به نظرتان می رسد با دیگران به اشتراک بگذارید
%PDF-1.5
%
1 0 obj
>/OCGs[5 0 R]>>/Pages 3 0 R/Type/Catalog>>
endobj
2 0 obj
>stream
application/pdf
Telfast Insert
2018-06-24T09:07:51+06:00
2018-06-24T09:07:51+06:00
2018-06-24T09:07:51+07:00
Adobe Illustrator CC 2014 (Windows)
256
180
JPEG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uuid:05fc9f28-d98d-4c83-9b84-0600e544e74b
xmp.did:5183f119-4cf6-3540-9dcc-4f89a24a029a
uuid:5D20892493BFDB11914A8590D31508C8
proof:pdf
uuid:95522137-f4f1-4a0b-8349-904723511e0b
xmp.did:6a2492f7-bd3d-2e4d-b6de-af199937f19a
uuid:5D20892493BFDB11914A8590D31508C8
proof:pdf
saved
xmp.iid:CBE10D7EC571E61182C9950F67DBD766
2016-09-03T16:59:31+06:00
Adobe Illustrator CS6 (Windows)
/
saved
xmp.iid:5183f119-4cf6-3540-9dcc-4f89a24a029a
2018-06-24T09:07:48+06:00
Adobe Illustrator CC 2014 (Windows)
/
Print
False
False
1
6.850000
10.000000
Inches
Black
PANTONE Process Black C
Default Swatch Group
0
White
CMYK
PROCESS
0.000000
0.000000
0.000000
0.000000
Black
CMYK
PROCESS
0.000000
0.000000
0.000000
100.000000
CMYK Red
CMYK
PROCESS
0.000000
100.000000
100.000000
0.000000
CMYK Yellow
CMYK
PROCESS
0.000000
0.000000
100.000000
0.000000
CMYK Green
CMYK
PROCESS
100.000000
0.000000
100.000000
0.000000
CMYK Cyan
CMYK
PROCESS
100.000000
0.000000
0.000000
0.000000
CMYK Blue
CMYK
PROCESS
100.000000
100.000000
0.000000
0.000000
CMYK Magenta
CMYK
PROCESS
0.000000
100.000000
0.000000
0.000000
C=15 M=100 Y=90 K=10
CMYK
PROCESS
15.000000
100.000000
90.000000
10.000000
C=0 M=90 Y=85 K=0
CMYK
PROCESS
0.000000
90.000000
85.000000
0.000000
C=0 M=80 Y=95 K=0
CMYK
PROCESS
0.000000
80.000000
95.000000
0.000000
C=0 M=50 Y=100 K=0
CMYK
PROCESS
0.000000
50.000000
100.000000
0.000000
C=0 M=35 Y=85 K=0
CMYK
PROCESS
0.000000
35.000000
85.000000
0.000000
C=5 M=0 Y=90 K=0
CMYK
PROCESS
5.000000
0.000000
90.000000
0.000000
C=20 M=0 Y=100 K=0
CMYK
PROCESS
20.000000
0.000000
100.000000
0.000000
C=50 M=0 Y=100 K=0
CMYK
PROCESS
50.000000
0.000000
100.000000
0.000000
C=75 M=0 Y=100 K=0
CMYK
PROCESS
75.000000
0.000000
100.000000
0.000000
C=85 M=10 Y=100 K=10
CMYK
PROCESS
85.000000
10.000000
100.000000
10.000000
C=90 M=30 Y=95 K=30
CMYK
PROCESS
90.000000
30.000000
95.000000
30.000000
C=75 M=0 Y=75 K=0
CMYK
PROCESS
75.000000
0.000000
75.000000
0.000000
C=80 M=10 Y=45 K=0
CMYK
PROCESS
80.000000
10.000000
45.000000
0.000000
C=70 M=15 Y=0 K=0
CMYK
PROCESS
70.000000
15.000000
0.000000
0.000000
C=85 M=50 Y=0 K=0
CMYK
PROCESS
85.000000
50.000000
0.000000
0.000000
C=100 M=95 Y=5 K=0
CMYK
PROCESS
100.000000
95.000000
5.000000
0.000000
C=100 M=100 Y=25 K=25
CMYK
PROCESS
100.000000
100.000000
25.000000
25.000000
C=75 M=100 Y=0 K=0
CMYK
PROCESS
75.000000
100.000000
0.000000
0.000000
C=50 M=100 Y=0 K=0
CMYK
PROCESS
50.000000
100.000000
0.000000
0.000000
C=35 M=100 Y=35 K=10
CMYK
PROCESS
35.000000
100.000000
35.000000
10.000000
C=10 M=100 Y=50 K=0
CMYK
PROCESS
10.000000
100.000000
50.000000
0.000000
C=0 M=95 Y=20 K=0
CMYK
PROCESS
0.000000
95.000000
20.000000
0.000000
C=25 M=25 Y=40 K=0
CMYK
PROCESS
25.000000
25.000000
40.000000
0.000000
C=40 M=45 Y=50 K=5
CMYK
PROCESS
40.000000
45.000000
50.000000
5.000000
C=50 M=50 Y=60 K=25
CMYK
PROCESS
50.000000
50.000000
60.000000
25.000000
C=55 M=60 Y=65 K=40
CMYK
PROCESS
55.000000
60.000000
65.000000
40.000000
C=25 M=40 Y=65 K=0
CMYK
PROCESS
25.000000
40.000000
65.000000
0.000000
C=30 M=50 Y=75 K=10
CMYK
PROCESS
30.000000
50.000000
75.000000
10.000000
C=35 M=60 Y=80 K=25
CMYK
PROCESS
35.000000
60.000000
80.000000
25.000000
C=40 M=65 Y=90 K=35
CMYK
PROCESS
40.000000
65.000000
90.000000
35.000000
C=40 M=70 Y=100 K=50
CMYK
PROCESS
40.000000
70.000000
100.000000
50.000000
C=50 M=70 Y=80 K=70
CMYK
PROCESS
50.000000
70.000000
80.000000
70.000000
PANTONE Process Black C
SPOT
100.000000
CMYK
0.000000
0.000000
0.000000
100.000000
Grays
1
C=0 M=0 Y=0 K=100
CMYK
PROCESS
0.000000
0.000000
0.000000
100.000000
C=0 M=0 Y=0 K=90
CMYK
PROCESS
0.000000
0.000000
0.000000
89.999400
C=0 M=0 Y=0 K=80
CMYK
PROCESS
0.000000
0.000000
0.000000
79.998800
C=0 M=0 Y=0 K=70
CMYK
PROCESS
0.000000
0.000000
0.000000
69.999700
C=0 M=0 Y=0 K=60
CMYK
PROCESS
0.000000
0.000000
0.000000
59.999100
C=0 M=0 Y=0 K=50
CMYK
PROCESS
0.000000
0.000000
0.000000
50.000000
C=0 M=0 Y=0 K=40
CMYK
PROCESS
0.000000
0.000000
0.000000
39.999400
C=0 M=0 Y=0 K=30
CMYK
PROCESS
0.000000
0.000000
0.000000
29.998800
C=0 M=0 Y=0 K=20
CMYK
PROCESS
0.000000
0.000000
0.000000
19.999700
C=0 M=0 Y=0 K=10
CMYK
PROCESS
0.000000
0.000000
0.000000
9.999100
C=0 M=0 Y=0 K=5
CMYK
PROCESS
0.000000
0.000000
0.000000
4.998800
Brights
1
C=0 M=100 Y=100 K=0
CMYK
PROCESS
0.000000
100.000000
100.000000
0.000000
C=0 M=75 Y=100 K=0
CMYK
PROCESS
0.000000
75.000000
100.000000
0.000000
C=0 M=10 Y=95 K=0
CMYK
PROCESS
0.000000
10.000000
95.000000
0.000000
C=85 M=10 Y=100 K=0
CMYK
PROCESS
85.000000
10.000000
100.000000
0.000000
C=100 M=90 Y=0 K=0
CMYK
PROCESS
100.000000
90.000000
0.000000
0.000000
C=60 M=90 Y=0 K=0
CMYK
PROCESS
60.000000
90.000000
0.003100
0.003100
Adobe PDF library 11.00
endstream
endobj
3 0 obj
>
endobj
7 0 obj
>/Resources>/ExtGState>/Properties>>>/Thumb 12 0 R/TrimBox[0.0 0.0 493.2 720.0]/Type/Page>>
endobj
8 0 obj
>stream
HWK%)*;UBY
Home » Telfast 120mg
Telfast’s same fast acting formula now comes in a new purple pack.
Fast, non drowsy relief of the symptoms of hayfever allergies. With just one tablet a day you can get on with your day without worrying about your allergies.
Always read the label. Follow the directions for use. If symptoms persist, talk to your health professional.
Available in packs of 10 and 20 tablets from your local pharmacy. Telfast 120mg strength is also available in packs of 5 and 10 at leading supermarkets.داروی telfast 120mg
Sugar, Gluten, Lactose
Click here to view the Consumer Medicine Information
Product
Telfast 120mg
Telfast 60mg
Telfast 180mg
Telfast Oral Liquid Kids
Active Ingredient
Fexofenadine Hydrochloride
Fexofenadine Hydrochloride
Fexofenadine Hydrochloride
Fexofenadine Hydrochloride
Strength
120mg – per tablet
60mg – per tablet
180mg – per tablet
30mg – per 5 mL
Directions
1 tablet daily as required
1 tablet twice daily as required
1 tablet daily as required
Itchy skin, From 6-23 months: 2.5mL twice daily as required
Age Indications
Adults and Children from 12years
Adults and Children from 12years
Adults and Children from 12years
Itchy skin: From 6 months
Product
Telfast 120mg
Telfast 60mg
Telfast 180mg
Telfast Oral Liquid Kids
داروی telfast 120mg
Benefit
Non-Drowsy
Fast-acting – works within 1 hour
24 Hour relief
Year round allergies
Gluten free
Sugar free
Lactose free
Product
Telfast 120mg
Telfast 60mg
Telfast 180mg
Telfast Oral Liquid Kids
Symptom
Relief
Sneezing
Runny or stuffy nose
Watery eyes
Itchy eyes, throat or nose
Itchy skin rash / hives
Swelling related to allergy / hives
Telfast 60mg is indicated for the relief of symptoms associated with allergic rhinitis in adults and children aged 12 years or older.
Telfast 120mg is indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children aged 12 years or older.
Telfast 180mg is indicated for the relief of symptoms associated with seasonal allergic rhinitis or urticaria in adults and children aged 12 years or older.
Telfast Oral Liquid is indicated for the relief of symptoms associated with urticaria from 6 months of age.
Relief of symptoms associated with seasonal allergic rhinitis from 2 years of age.
Telfast tablets contain an active ingredient called “fexofenadine”. It is one of a group of medicines called antihistamines.
Telfast 120mg is used to relieve the symptoms of hayfever (seasonal allergic rhinitis) such as sneezing, itchy, watery or red eyes, and itchy, blocked or runny nose. It works by blocking the action of histamine which causes these unwanted effects. Telfast is a non-sedating antihistamine which means it has been shown not to make you drowsy or slow down your reactions.
Do not take Telfast, and tell your doctor or pharmacist if:
You should inform your pharmacist/doctor if:
Your pharmacist/doctor will consider these points when recommending Telfast.
Use in children: There is currently not enough information available to recommend Telfast 120mg for use in children under 12 years of age. Telfast Oral Liquid Kids may be suitable.
Take Telfast with a glass of water. It may be taken with or without food.
For the relief of the symptoms of hayfever, the usual dosage for adults and children over 12 years of age is one Telfast 120mg tablet daily when required.
Do not take more than the recommended dose and remember, this medicine is for you. Do not give it to anyone else, even if their symptoms seem to be the same as yours.
If Telfast does not relieve your symptoms, do not take extra tablets. Tell your doctor or pharmacist.
If you think that you or someone else may have taken too much Telfast – (even if there are no signs of discomfort or poisoning) – contact your doctor or Poisons Information Centre, or go to the Casualty Department at your nearest hospital.
Tell your doctor or pharmacist as soon as possible if you do not feel well while taking Telfast, even if you do not think the problem is connected with the medicine or is not listed here.
All medicines can cause side effects. Although most people will not experience any, some of the side effects that may occur with Telfast are:
These same effects were seen in patients taking dummy or placebo capsules during the clinical studies.
Keep your tablets in a safe place out of the reach of children. Store the tablets at room temperature below 30 degrees Celsius.
Disposal: Return any unwanted tablets to your pharmacist.
Telfast 120mg tablets are peach coloured and have a modified capsule shape.
Telfast 120mg is available in blister packs of 5, 10 or 30 tablets.
Each Telfast 120mg tablet contains 120mg of the active ingredient fexofenadine hydrochloride.
The inactive ingredients in Telfast are: croscarmellose sodium, pregelatinised maize starch, microcrystalline cellulose, magnesium stearate, hypromellose, povidone, titanium dioxide, colloidal anhydrous silica, macrogol 400 and iron oxide.
Telfast does not contain any gluten, lactose or preservatives.
CHCANZ.CFEX.19.04.0434c
For your nearest Telfast stockist, search by entering your location:
Always read the label. Use only as directed. If symptoms persist, please see your healthcare professional.
© 2019 Telfast. (Active ingredient: fexofenadine hydrochloride) Telfast is a Registered Trademark of Sanofi-aventis Healthcare Pty Ltd, trading as Sanofi Consumer Healthcare. A.C.N 076 651 959. CHCANZ.CFEX.19.04.0434c. For Australian residents only. Last updated 17th May 2019.
The liability of the Company or of SANOFI shall not be incurred by a third party site that can be accessed via the Site. We do not have any way of controlling the content of such third party sites which remain entirely independent of the Company. Moreover, the existence of a link between the Site and a third party site does not under any circumstances mean that the Company approves the content of that site in any way whatsoever and in particular the use that may be made of it.
If you’d like to know which product might be suitable for your needs, or if you have questions relating to any of our products, please fill in the form below. We’d love to hear from you. To speak with a team member or report an adverse event, please call 1800 818 806 within Australia.
Thank you for your submission. A representative will be in contact shortly.
%PDF-1.6
%
104 0 obj >
endobj
xref
104 29
0000000016 00000 n
0000001362 00000 n
0000001499 00000 n
0000001581 00000 n
0000001713 00000 n
0000001977 00000 n
0000002531 00000 n
0000002567 00000 n
0000002613 00000 n
0000002659 00000 n
0000002704 00000 n
0000002750 00000 n
0000003018 00000 n
0000003095 00000 n
0000004321 00000 n
0000004802 00000 n
0000005052 00000 n
0000005458 00000 n
0000005714 00000 n
0000050089 00000 n
0000052759 00000 n
0000052927 00000 n
0000058592 00000 n
0000058688 00000 n
0000059747 00000 n
0000059813 00000 n
0000060570 00000 n
0000060746 00000 n
0000000897 00000 n
trailer
]>>
startxref
0
%%EOF
132 0 obj>stream
ûT”W{9ARMәܔo’;TmVuK’.Fq,;s”i$Oԓf9!”oA
wA2.Cz6gYL;b)iL
Label 5 – Do not take indigestion remedies 2 hours before or after you take this medicine
© NICE 2019. All rights reserved. Subject to Notice of rights.
